AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Calidi Biotherapeutics shares surge 16.87% premarket after partnering with Matica Bio to advance oncolytic virus manufacturing for IND.
ByAinvest
Friday, Nov 7, 2025 4:17 am ET1min read
Calidi Biotherapeutics Inc. (CLDI) surged 16.87% in premarket trading following multiple positive developments. The company announced a partnership with Matica Bio, a leader in oncolytic virus manufacturing, to advance its IND application for an oncology candidate, signaling progress in its drug development pipeline. Additionally, Calidi disclosed new data on its lead therapeutic, CLD-401, to be presented at the 2025 SITC Annual Meeting, bolstering investor confidence in its clinical-stage assets. Recent news of a scientific advisory board appointment and a reverse stock split further reinforced strategic momentum. These developments, particularly the Matica collaboration and data presentation, align with the stock’s sharp premarket ascent, reflecting optimism about its pipeline advancements and operational execution.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet